> A new study concludes that clinical trials funded by drug companies are more likely to lead to positive results than trials funded by not-for-profit groups. Report [1]
> TorryPines says its Phase I trial for its therapeutic candidate for acute migraines has produced positive data. Report [2]
> Cambridge, MA-based Vertex has launched a Phase I trial of VX-770 as a therapy for cystic fibrosis. Report [3]
> Amarin has acquired global rights to a novel oral formulation of apomorphine for the treatment of "off" episodes in patients with advanced Parkinson's disease. Release [4]
> Genentech will collaborate with Immunogen to develop a manufacturing process for Herceptin. Release [5]
> Intercept Pharmaceuticals has garnered $41 million in equity financing. The financing was led by Milan-based Genextra. Release [6]
> PrimeGen Biotech has created a wholly owned subsidiary--PrimeCell Therapeutics. Release [7]
And Finally… Indonesia has reported five more deaths from bird flu. Article [8]
Links:
[1] http://www.forbes.com/forbeslife/health/feeds/hscout/2006/05/16/hscout532732.html
[2] http://www.pharmaceutical-business-review.com/article_news.asp?guid=95FCA6C0-7354-4F10-B8B7-F2F0ED2138EB
[3] http://boston.bizjournals.com/boston/stories/2006/05/15/daily23.html?jst=b_ln_hl
[4] http://www.pharmalive.com/News/index.cfm?articleid=341944&categoryid=10
[5] http://www.in-pharmatechnologist.com/news/ng.asp?n=67747-genentech-immunogen-trastuzumab-dm-wyeth-antibody-guided-delivery
[6] http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/05-16-2006/0004362403&EDATE=
[7] http://www.pharmalive.com/News/index.cfm?articleid=341421&categoryid=15
[8] http://www.bbc.co.uk/worldservice/learningenglish/newsenglish/witn/2006/05/060517_bird_flu.shtml